Trial Profile
A pharmacokinetic study of extended-release formulation of SPN-812 for the treatment of attention deficit hyperactivity disorder (ADHD)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Nov 2014
Price :
$35
*
At a glance
- Drugs Viloxazine (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Pharmacokinetics
- 03 Nov 2014 New trial record